PET radiometals for antibody labeling
Journal of Labelled Compounds and Radiopharmaceuticals · 2018-07 · 61 (9) · 636-651
DOI: 10.1002/jlcr.3607 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, online erschienen am 12.03.2018. Verfasst von Eduardo Aluicio-Sarduy und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin-Madison, Department of Medical Physics, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Recent advances in molecular characterization of tumors have made possible the emergence of new types of cancer therapies where traditional cytotoxic drugs and nonspecific chemotherapy can be complemented with targeted molecular therapies. One of the main revolutionary treatments is the use of monoclonal antibodies (mAbs) that selectively target the disseminated tumor cells while sparing normal tissues. mAbs and related therapeutics can be efficiently radiolabeled with a wide range of radionuclides to facilitate preclinical and clinical studies. Non‐invasive molecular imaging techniques, such as Positron Emission Tomography (PET), using radiolabeled mAbs provide useful information on the whole‐body distribution of the biomolecules, which may enable patient stratification, diagnosis, selection of targeted therapies, evaluation of treatment response, and prediction of dose limiting tissue and adverse effects. In addition, when mAbs are labeled with therapeutic radionuclides, the combination of immunological and radiobiological cytotoxicity may result in enhanced treatment efficacy. The pharmacokinetic profile of antibodies demands the use of long half‐life isotopes for longitudinal scrutiny of mAb biodistribution and precludes the use of well‐stablished short half‐life isotopes. Herein, we review the most promising PET radiometals with chemical and physical characteristics that make the appealing for mAb labeling, highlighting those with theranostic radioisotopes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Wisconsin-Madison, Department of Medical Physics, Madison, Wisconsin, USA.
- University of Wisconsin-Madison, Department of Radiology, Madison, Wisconsin, USA.
- University of Wisconsin-Madison Carbone Cancer Center, Carbon Cancer Center, Madison, Wisconsin, USA.
ORCID-Profile: Eduardo Aluicio-Sarduy
Förderung
- NCI NIH HHS
Zitieren
APA
Aluicio-Sarduy, E., Ellison, P. A., Barnhart, T. E., Cai, W., Nickles, R. J., & Engle, J. W. (2018). PET radiometals for antibody labeling. Journal of Labelled Compounds and Radiopharmaceuticals, 61(9), 636-651. https://doi.org/10.1002/jlcr.3607
Vancouver
Aluicio-Sarduy E, Ellison PA, Barnhart TE, Cai W, Nickles RJ, Engle JW. PET radiometals for antibody labeling. Journal of Labelled Compounds and Radiopharmaceuticals. 2018;61(9):636-651. doi:10.1002/jlcr.3607
BibTeX
@article{AluicioSarduy2018,
author = {Aluicio-Sarduy, Eduardo and Ellison, Paul A and Barnhart, Todd E and Cai, Weibo and Nickles, Robert Jerry and Engle, Jonathan W},
title = {PET radiometals for antibody labeling},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2018},
volume = {61},
number = {9},
pages = {636--651},
doi = {10.1002/jlcr.3607}
}
EUVIMED